Andrea Penaloza

Andrea Penaloza

Auto-generated profile, based on publicly available information

Andrea Penaloza

F-CRIN, INNOVTE , Saint-Etienne , France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Annals of Internal Medicine
Verified
Journal Article
Closed access
MRMelanie Roussel
Melanie Roussel
BBBen Bloom
Ben Bloom
MTMehdi Taalba
Mehdi Taalba
CCChristophe Choquet
Christophe Choquet
DDDelphine Douillet
Delphine Douillet
YYYouri Yordanov
Youri Yordanov
Recently, validated clinical decision rules have been developed that avoid unnecessary use of computed tomographic pulmonary angiography (CTPA) in patients with suspected pulmonary embolism (PE) in the emergency department (ED). To measure any resulting change in CTPA use for suspected PE. Retrospective analysis. 26 European EDs in 6 countries. Patients with CTPA performed for suspected PE in the ED during the first 7 days of each odd month between January 2015 and December 2019. The primary end points were the CTPAs done for suspected PE in the ED and the number of PEs diagnosed in the ED each year adjusted to an annual census of 100 000 ED visits. Temporal trends were estimated using generalized linear mixed regression models. 8970 CTPAs were included (median age, 63 years; 56% female). Statistically significant temporal trends for more frequent use of CTPA (836 per 100 000 ED visits in 2015 vs. 1112 in 2019; P < 0.001), more diagnosed PEs (138 per 100 000 in 2015 vs. 164 in 2019; P = 0.028), a higher proportion of low-risk PEs (annual percent change [APC], 13.8% [95% CI, 2.6% to 30.1%]) with more ambulatory management (APC, 19.3% [CI, 4.1% to 45.1%]), and a lower proportion of intensive care unit admissions (APC, -8.9% [CI, -17.1% to -0.3%]) were observed. Data were limited to 7 days every 2 months. Despite the recent validation of clinical decision rules to limit the use of CTPA, an increase in the CTPA rate along with more diagnosed PEs and especially low-risk PEs were instead observed. None specific for this study.

1 August 2012 in Current Opinion in Critical Care
Verified
Journal Article
Closed access
APAndrea Penaloza
Andrea Penaloza
PRPierre-Marie Roy
Pierre-Marie Roy
JKJeffrey Kline
Jeffrey Kline
Pulmonary embolism remains one of the leading causes of cardiovascular mortality. The wide range of reported mortality rates reflects heterogeneity in comorbidity and severity of pulmonary embolism. Optimizing risk stratification to prognose pulmonary embolism patients appears to be important to improve management, treatment and clinical outcome. Hemodynamic status is the most important short-term prognostic factor. High-risk pulmonary embolism or massive pulmonary embolism is defined by the patient response more than the clot size: patients with circulatory shock including sustained hypotension should receive thrombolytic therapy in absence of contraindications. Nonmassive or normotensive pulmonary embolism can be further stratified using clinical features, imaging (echocardiography, computed tomography) and biomarkers (troponins, natriuretic peptides): low-risk pulmonary embolism, evaluated by clinical model (Pulmonary Embolism Severity Index; PESI) can potentially be treated as outpatients; and intermediate-risk pulmonary embolism, which can be further stratified into less-severe and more-severe intermediate risk. The last may benefit from intensive clinical surveillance but the risk-benefit ratio for thrombolysis has been inadequately quantified to make any strong recommendation. New anticoagulants may transform traditional pulmonary embolism treatment. Optimizing risk stratification of patients with normotensive pulmonary embolism before they develop overt hemodynamic instability is the challenge of current pulmonary embolism management. Treatment strategy has to integrate this risk stratification and new anticoagulants arrival.

2 March 2018 in Internal and Emergency Medicine
Verified
Journal Article
Closed access
PDF file
TMThomas Moumneh
Thomas Moumneh
VRVanessa Richard-Jourjon
Vanessa Richard-Jourjon
EFEmilie Friou
Emilie Friou
FPFabrice Prunier
Fabrice Prunier
CSCaroline Soulie-Chavignon
Caroline Soulie-Chavignon
PRPierre Marie Roy
Pierre Marie Roy

12 July 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
DLDieuwke Luijten
Dieuwke Luijten
DDDelphine Douillet
Delphine Douillet
KLKim Luijken
Kim Luijken
CTCecile Tromeur
Cecile Tromeur
APAndrea Penaloza
Andrea Penaloza
FKFrederikus A. Klok
Frederikus A. Klok
Home treatment is considered safe in acute pulmonary embolism (PE) patients selected by a validated triage tool (e.g. simplified PE severity index score or Hestia rule), but there is uncertainty regarding the applicability in underrepresented subgroups. The aim was to evaluate the safety of home treatment by performing an individual patient-level data meta-analysis. Ten prospective cohort studies or randomized controlled trials were identified in a systematic search, totalling 2694 PE patients treated at home (discharged within 24 h) and identified by a predefined triage tool. The 14- and 30-day incidences of all-cause mortality and adverse events (combined endpoint of recurrent venous thromboembolism, major bleeding, and/or all-cause mortality) were evaluated. The relative risk (RR) for 14- and 30-day mortalities and adverse events is calculated in subgroups using a random effects model. The 14- and 30-day mortalities were 0.11% [95% confidence interval (CI) 0.0–0.24, I2 = 0) and 0.30% (95% CI 0.09–0.51, I2 = 0). The 14- and 30-day incidences of adverse events were 0.56% (95% CI 0.28–0.84, I2 = 0) and 1.2% (95% CI 0.79–1.6, I2 = 0). Cancer was associated with increased 30-day mortality [RR 4.9; 95% prediction interval (PI) 2.7–9.1; I2 = 0]. Pre-existing cardiopulmonary disease, abnormal troponin, and abnormal (N-terminal pro–)B-type natriuretic peptide [(NT-pro)BNP] at presentation were associated with an increased incidence of 14-day adverse events [RR 3.5 (95% PI 1.5–7.9, I2 = 0), 2.5 (95% PI 1.3–4.9, I2 = 0), and 3.9 (95% PI 1.6–9.8, I2 = 0), respectively], but not mortality. At 30 days, cancer, abnormal troponin, and abnormal (NT-pro)BNP were associated with an increased incidence of adverse events [RR 2.7 (95% PI 1.4–5.2, I2 = 0), 2.9 (95% PI 1.5–5.7, I2 = 0), and 3.3 (95% PI 1.6–7.1, I2 = 0), respectively]. The incidence of adverse events in home-treated PE patients, selected by a validated triage tool, was very low. Patients with cancer had a three- to five-fold higher incidence of adverse events and death. Patients with increased troponin or (NT-pro)BNP had a three-fold higher risk of adverse events, driven by recurrent venous thromboembolism and bleeding. Safety of home treatment of acute pulmonary embolism in the overall population and clinically relevant patient subgroups. (NT-pro)BNP, (N-terminal pro–)B-type natriuretic peptide; PE, pulmonary embolism; VTE, venous thromboembolism.

1 January 2015 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
CMCédric Van Marcke
Cédric Van Marcke
ADAnas Daoudia
Anas Daoudia
APAndrea Penaloza
Andrea Penaloza
FVFranck Verschuren
Franck Verschuren
An early differential diagnosis is mandatory when facing a patient with clinical shock of unclear aetiology, in order to guide proper treatment. We assessed if the expired CO2 measurement and alveolar-arterial CO2 calculation could improve the differential diagnosis of shock during its initial presentation, particularly in separating pulmonary embolism from other causes of shock. We analysed the charts of 12 patients who presented with clinical shock and had end-tidal CO2 (EtCO2) and arterial CO2 partial pressure (PaCO2) measurements. In cases with pulmonary embolism-related shock (n = 3), the gradient between PaCO2 and EtCO2 was increased (37 vs 0.2 mmHg). There was a similar trend for a higher PaCO2 value (60 vs 32.2 mmHg) and a lower EtCO2 value (23 vs 32 mmHg). An initial CO2 measurement might be an easily available tool for the early diagnostic work-up of clinical shock.

1 August 2020 in European Journal of Emergency Medicine
Verified
Journal Article
Open access
DDDelphine Douillet
Delphine Douillet
APAndrea Penaloza
Andrea Penaloza
DHDaniel Horner
Daniel Horner
DSDominique Savary
Dominique Savary
OHohugli Hugli
ohugli Hugli
PRPierre Marie Roy
Pierre Marie Roy